<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8"><meta name="generator" content="ABBYY FineReader 15"><title>C:\iTools\WMS\TandF-Journals\3125591\WorkingFolder\UATY_A_659324.dvi</title>
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:4pt Arial, sans-serif; }
 .font1 { font:6pt Arial, sans-serif; }
 .font2 { font:7pt Arial, sans-serif; }
 .font3 { font:8pt Arial, sans-serif; }
 .font4 { font:9pt Arial, sans-serif; }
 .font5 { font:10pt Arial, sans-serif; }
 .font6 { font:12pt Arial, sans-serif; }
 .font7 { font:15pt Calibri, sans-serif; }
 .font8 { font:7pt Segoe UI, sans-serif; }
 .font9 { font:8pt Segoe UI, sans-serif; }
 .font10 { font:9pt Segoe UI, sans-serif; }
 .font11 { font:10pt Segoe UI, sans-serif; }
 .font12 { font:8pt Times New Roman, serif; }
 .font13 { font:10pt Times New Roman, serif; }
 .font14 { font:27pt Times New Roman, serif; }
 .font15 { font:10pt Trebuchet MS, sans-serif; }
 .font16 { font:16pt Trebuchet MS, sans-serif; }
 .font17 { font:10pt Verdana, sans-serif; }

</style>
</head>
<body>
<p><span class="font17">This article was downloaded by: [McMaster University]</span></p>
<p><span class="font17">On: 28 December 2014, At: 11:49</span></p>
<p><span class="font17">Publisher: Taylor &amp; Francis</span></p>
<p><span class="font17">Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK</span></p><div><img src="Sablier et al. - 2012 - Ecolog_files/Sablier et al. - 2012 - Ecolog-1.jpg" alt="" style="width:123pt;height:157pt;"></div><br clear="all">
<p><span class="font16" style="font-weight:bold;">Assistive Technology: The Official Journal of RESNA</span></p>
<p><span class="font15">Publication details, including instructions for authors and subscription information: </span><a href="http://www.tandfonline.com/loi/uaty20"><span class="font15" style="text-decoration:underline;">http://www.tandfonline.com/loi/uaty20</span></a></p>
<p><span class="font16" style="font-weight:bold;">Ecological Assessments of Activities of Daily Living and Personal Experiences with Mobus, An&nbsp;Assistive Technology for Cognition: A Pilot Study in&nbsp;Schizophrenia</span></p>
<p><span class="font15">Juliette Sablier PhD <sup>a b</sup> , Emmanuel Stip MD MSc <sup>b</sup> , Pierre Jacquet PhD <sup>c</sup> , Sylvain Giroux PhD <sup>d</sup> , Helene Pigot PhD <sup>d</sup> , Mobus group <sup>e</sup> &amp; Nicolas Franck MD PhD <sup>c&nbsp;a</sup> Neuroscience Cognitive Center CNRS UMR 5229 , University of Lyon &amp; Le Vinatier Hospital ,&nbsp;France&nbsp;<sup>b</sup> Fernand Seguin Research Centre , University of Montreal &amp; Louis-H. Lafontaine Hospital ,&nbsp;Canada</span></p>
<p><span class="font15"><sup>c</sup> Neuroscience Cognitive Center CNRS UMR 5229 , University of Lyon &amp; Le Vinatier Hospital (Rehabilitation Center) , France</span></p>
<p><span class="font15"><sup>d</sup> DOMUS Laboratory , University of Sherbrooke , Quebec , Canada</span></p>
<p><span class="font15"><sup>e</sup> Mobus group is composed of: Programmers at DOMUS Laboratory of the University of Sherbrooke , Quebec , Canada , Bouchard, F., Marcotte, N., Viboud, J.P.; Psychiatrists&nbsp;at Louis-H. Lafontaine Hospital (Quebec, Canada): Bentaleb, L.A., Landry, P., Lipp, O.,&nbsp;Tranulis, C., Villeneuve, M.; Ergotherapists at Louis-H. Lafontaine Hospital (Quebec,&nbsp;Canada): Cloutier, C., Lalancette, C., Prince, A.; Pharmacists at Louis-H. Lafontaine Hospital&nbsp;(Quebec, Canada): Vincent, P., Lum, M.; Social worker at Vinatier Hospital (Lyon, France):&nbsp;Berrube, M.C.; Beneficiaries attendant at Louis-H. Lafontaine Hospital (Quebec, Canada):&nbsp;Lucas, M.; Nurses and psychologist at Vinatier Hospital (Lyon, France): Boisset, G., Guida,&nbsp;M., Mazuire, J., Meylan, F., Meynier, J., Pelletier, G, Sportiello, S.; Students at University of&nbsp;Montreal (Quebec, Canada): Dore-Gauthier, V., Guevremont, C., Nadeau-Marcotte, F.&nbsp;Accepted author version posted online: 06 Apr 2012.Published online: 06 Jun 2012.</span></p>
<p><span class="font15" style="font-weight:bold;">To cite this article: </span><span class="font15">Juliette Sablier PhD , Emmanuel Stip MD MSc , Pierre Jacquet PhD , Sylvain Giroux PhD , Helene Pigot PhD , Mobus group &amp; Nicolas Franck MD PhD (2012) Ecological Assessments of Activities of Daily Living and Personal&nbsp;Experiences with Mobus, An Assistive Technology for Cognition: A Pilot Study in Schizophrenia, Assistive Technology: The&nbsp;Official Journal of RESNA, 24:2, 67-77, DOI: </span><span class="font15" style="text-decoration:underline;">10.1080/10400435.2012.659324</span></p>
<p><span class="font15" style="font-weight:bold;">To link to this article:</span><a href="http://dx.doi.org/10.1080/10400435.2012.659324"><span class="font15" style="font-weight:bold;"> </span><span class="font15" style="text-decoration:underline;">http://dx.doi.org/10.1080/10400435.2012.659324</span></a></p>
<p><span class="font17">PLEASE SCROLL DOWN FOR ARTICLE</span></p>
<p><span class="font17">Taylor &amp; Francis makes every effort to ensure the accuracy of all the information (the &quot;Content&quot;) contained in the publications on our platform. However, Taylor &amp; Francis, our agents, and our licensors make no&nbsp;representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the&nbsp;Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and&nbsp;are not the views of or endorsed by Taylor &amp; Francis. The accuracy of the Content should not be relied upon and&nbsp;should be independently verified with primary sources of information. Taylor and Francis shall not be liable for&nbsp;any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever&nbsp;or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of&nbsp;the Content.</span></p>
<p><span class="font17">This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any&nbsp;form to anyone is expressly forbidden. Terms &amp; Conditions of access and use can be found at</span><a href="http://www.tandfonline.com/page/terms-and-conditions"><span class="font17"> </span><span class="font17" style="text-decoration:underline;">http://</span></a><span class="font17" style="text-decoration:underline;">&nbsp;</span><a href="http://www.tandfonline.com/page/terms-and-conditions"><span class="font17" style="text-decoration:underline;">www.tandfonline.com/page/terms-and-conditions</span></a></p><div>
<p><span class="font13">Downloaded by [McMaster University] at 11:49 28 December 2014</span></p></div><br clear="all">
<p><span class="font9" style="font-weight:bold;font-style:italic;">Assistive Technology</span><span class="font1" style="font-weight:bold;font-style:italic;">®</span><span class="font9" style="font-style:italic;">, 24'.6~I-~n,</span><span class="font9"> 2012</span></p>
<p><span class="font9">Copyright© 2012 RESNA</span></p>
<p><span class="font9">ISSN: 1040-0435 print/1949-3614 online</span></p>
<p><span class="font9">DOI: 10.1080/10400435.2012.659324</span></p><div>
<p><span class="font3" style="font-weight:bold;">Taylor &amp; Francis</span></p>
<p><span class="font0" style="font-weight:bold;font-style:italic;">&lt; J</span><span class="font0" style="font-weight:bold;"> Taylor &amp; Francis Croup</span></p></div><br clear="all">
<p><span class="font14">Ecological Assessments of Activities of Daily Living and Personal Experiences with&nbsp;Mobus, An Assistive Technology for&nbsp;Cognition: A Pilot Study in Schizophrenia</span></p><div>
<p><span class="font13">Downloaded by [McMaster University] at 11:49 28 December 2014</span></p></div><br clear="all"><div>
<p><span class="font4" style="font-weight:bold;">Juliette Sablier, PhD,<sup>1 </sup>Emmanuel Stip, MD, MSc,<sup>2&nbsp;</sup>Pierre Jacquet, PhD,<sup>3</sup> Sylvain&nbsp;Giroux, PhD,<sup>4</sup> Helene Pigot,&nbsp;PhD,<sup>4</sup> Mobus group,<sup>5</sup> and&nbsp;Nicolas Franck, MD, PhD<sup>3</sup></span></p>
<p><span class="font8">1</span></p>
<p><span class="font8">Neuroscience Cognitive Center CNRS UMR 5229, University of Lyon &amp; Le Vinatier&nbsp;Hospital, France; and Fernand Seguin&nbsp;Research Centre, University of Montreal &amp;&nbsp;Louis-H. Lafontaine Hospital, Canada&nbsp;<sup>2</sup>Fernand Seguin Research Centre, University&nbsp;of Montreal &amp; Louis-H. Lafontaine Hospital,&nbsp;Canada&nbsp;<sup>3</sup>Neuroscience Cognitive Center CNRS UMR&nbsp;5229, University of Lyon &amp; Le Vinatier&nbsp;Hospital (Rehabilitation Center), France&nbsp;<sup>4</sup>DOMUS Laboratory, University of&nbsp;Sherbrooke, Quebec, Canada&nbsp;<sup>5</sup>Mobus group is composed of: Programmers&nbsp;at DOMUS Laboratory of the University of&nbsp;Sherbrooke (Quebec, Canada): Bouchard, F.,&nbsp;Marcotte, N., Viboud, J.P.; Psychiatrists at&nbsp;Louis-H. Lafontaine Hospital (Quebec,&nbsp;Canada): Bentaleb, L.A., Landry, P., Lipp, O.,&nbsp;Tranulis, C., Villeneuve, M.; Ergotherapists at&nbsp;Louis-H. Lafontaine Hospital (Quebec,&nbsp;Canada): Cloutier, C., Lalancette, C., Prince,&nbsp;A.; Pharmacists at Louis-H. Lafontaine&nbsp;Hospital (Quebec, Canada): Vincent, P., Lum,&nbsp;M.; Social worker at Vinatier Hospital (Lyon,&nbsp;France): Berrube, M.C.; Beneficiaries&nbsp;attendant at Louis-H. Lafontaine Hospital&nbsp;(Quebec, Canada): Lucas, M.; Nurses and&nbsp;psychologist at Vinatier Hospital (Lyon,&nbsp;France): Boisset, G., Guida, M., Mazuire, J.,&nbsp;Meylan, F., Meynier, J., Pelletier, G, Sportiello,&nbsp;S.; Students at University of Montreal&nbsp;(Quebec, Canada): Dore-Gauthier, V.,&nbsp;Guevremont, C., Nadeau-Marcotte, F.</span></p></div><br clear="all"><div>
<p><span class="font3">Address correspondence to Juliette Sablier, 67 Boulevard Pinel,&nbsp;69675 Bron Cedex, France. E-mail:&nbsp;</span><a href="mailto:juliette.sablier@agim.eu"><span class="font3">juliette.sablier@agim.eu</span></a></p></div><br clear="all">
<p><span class="font4" style="font-weight:bold;">ABSTRACT </span><span class="font13">Mobus is a cognitive orthotic designed for people with difficulties managing Activities of Daily Living (ADL), as encountered in schizophrenia. It provides a schedule manager as well as the possibility to&nbsp;report occurrences of symptomatic experiences. Receiving this information by&nbsp;Internet, caregivers can assist the patient rehabilitation process. Our aim was&nbsp;to explore the use and satisfaction of Mobus by people with schizophrenia.&nbsp;Nine outpatients tested Mobus for 6 weeks. Indicators of cognitive functioning&nbsp;and autonomy were measured with the CAmbridge Neuropsychological Tests&nbsp;Automated Battery (CANTAB) and the Independant Living Skills Scale (ILSS).&nbsp;On average, 42.6% of the planned ADL were validated and more than 1 symptom per week were reported. Mainly because of technical breakdown, more&nbsp;than 50% of the outpatients evaluated the Mobus satisfaction below 1.7/5, nevertheless 3 participants appreciated it greatly. Some enhancements were found&nbsp;on subscales of CANTAB and ILSS and some participants reported that they&nbsp;acquired planning skills by using Mobus. To ensure ease of use, refinements&nbsp;are needed from rehabilitation and technical approaches, especially to personalize the device. Discussions on ethical and methodological issues lead to an&nbsp;improved version of Mobus that will be tested with a larger sample size.</span></p>
<p><span class="font11" style="font-weight:bold;">KEYWORDS </span><span class="font10">activities of daily living, assistive technology for cognition, cognitive remediation, executive functioning, MOBUS, schizophrenia, smart phone</span></p><a name="caption1"></a>
<h1><a name="bookmark0"></a><span class="font7" style="font-weight:bold;">INTRODUCTION</span></h1>
<p><span class="font13">Schizophrenia is defined as a chronic psychosis that affects approximately 1% of the world’s adults. It is characterized by positive (hallucinations, delusions,&nbsp;disorganized behavior . . .) and negative symptoms (social avoidance, blunted&nbsp;affect, apragmatism . . .). Antipsychotics help to control these symptoms, but</span></p><div>
<p><span class="font13">Downloaded by [McMaster University] at 11:49 28 December 2014</span></p></div><br clear="all">
<p><span class="font13">cognitive impairments remain by most of schizophrenia people, and have functional impacts (Bowie &amp; Harvey, 2005; Green, 1996). In particular, deficits in&nbsp;memory and executive functions lead to difficulties in&nbsp;planning Activities of Daily Living (ADL) (Chambon&nbsp;et al., 2008; Norman et al., 1999). Most of individuals with schizophrenia are indeed unable to assume&nbsp;social responsibilities such as finding a job, establishing interpersonal relationships, or living on their own.&nbsp;These difficulties represent barriers to autonomy and&nbsp;in performing social roles.</span></p>
<p><span class="font13">The evolution of new technologies contributes to provide remote services for patients as well as for&nbsp;caregivers by developing interactive assistance systems. Assistive Technology for Cognition (ATC), also&nbsp;referred as a “cognitive orthotic” or “prosthetic” (Cole,&nbsp;1999; LoPresti, Mihailidis, &amp; Kirsch, 2004) can be considered as a “crutch for the mind.” It has the advantage&nbsp;of being highly customizable, so that one can directly&nbsp;assist each patient in performing his ADL (LoPresti&nbsp;et al., 2004; Sablier, Stip, &amp; Franck, 2009). Furthermore,&nbsp;these kinds of tools have positive social impacts, as&nbsp;they represent modernity, and are commonly perceived&nbsp;as making life more simple and enjoyable. With the&nbsp;advance of telecommunication, telecare systems offer&nbsp;an opportunity in assisting people anywhere at any&nbsp;time, providing ecological strategies of treatment. For&nbsp;example, Neuropage is a device aimed at assisting people with memory impairments to remember their ADL&nbsp;(Wilson, Emslie, Quirk, &amp; Evans, 2001; Wilson, Evans,&nbsp;Emslie, &amp; Malinek, 1997). It is a pager, for example, a&nbsp;little device composed of a screen where one line of&nbsp;text can be displayed, and one on</span><span class="font13" style="font-style:italic;">/</span><span class="font13">off button. Its use is&nbsp;extremely simplified in order to minimize the need of&nbsp;memory skills. The tool is linked to a paging company&nbsp;which sends messages automatically. These messages&nbsp;are chosen beforehand by the user (patient with memory deficits), in accordance with his</span><span class="font13" style="font-style:italic;">/</span><span class="font13">her caregiver. The&nbsp;patient is also an actor of his</span><span class="font13" style="font-style:italic;">/</span><span class="font13">her own treatment, and&nbsp;he</span><span class="font13" style="font-style:italic;">/</span><span class="font13">she takes decisions about the planning of his</span><span class="font13" style="font-style:italic;">/</span><span class="font13">her&nbsp;daily life. A ringtone alerts the patient when an activity&nbsp;has to be achieved. The use of Neuropage improved significantly the memory skills of more than 80% of the&nbsp;patients who achieved the experiment (Wilson et al.,&nbsp;2001). These improvements remained at least seven&nbsp;weeks after the end of use. This tool is also hopeful&nbsp;for people with memory impairments due to various pathologies. Nevertheless, its use is too simple&nbsp;for people with schizophrenia, who have more preserved memory skills than participants of the Wilson’s&nbsp;studies. As a matter of fact, it is important to propose tools adapted to the skills of targeted users, for&nbsp;example, not too simple, in order to motivate people to use them, but not too complex, in order to&nbsp;avoid discouragement. For example, the Planning and&nbsp;Execution Assistant and Training (PEAT), developed&nbsp;by Levinson (1997), offers the advantage of being very&nbsp;individualized. This system is able to change its plans&nbsp;in case of unexpected event. It creates also the best plan&nbsp;and provides visual and auditive interface for assisting&nbsp;the user. However, this user-interface is too sophisticated and complex for being used by people with&nbsp;cognitive impairments such as schizophrenia (Giroux&nbsp;et al., 2008). The challenge is also to balance easiness&nbsp;and complexity in order to develop ATC according&nbsp;to the needs and skills of targeted users. Granholm,&nbsp;Loh, and Swendsen asked 54 schizophrenia or schizoaffective people to test the Computerized Ecological&nbsp;Momentary Assessment (EMAc) (Granholm, Loh, &amp;&nbsp;Swendsen, 2009). EMAc provides ecological measures&nbsp;of behavior, symptoms, as well as emotion. Patients&nbsp;were asked to fulfill a questionnaire on a Personal&nbsp;Digital Assistant (PDA) four times a day during one&nbsp;week. Recorded data was linked to scores at standardized assessment scales of daily functioning. Through&nbsp;this study, authors showed that EMAc was a valid and&nbsp;feasible approach for collecting ecological data about&nbsp;schizophrenia people. Finally, since 2003, the Research&nbsp;Laboratory on Domotics and Mobile computing of the&nbsp;University of Sherbrooke, Quebec, Canada (DOMUS)&nbsp;has been developing systems on PDAs for people with&nbsp;cognitive impairments, which eventually lead to the&nbsp;birth of Mobus (Giroux et al., 2008). This software&nbsp;supplies cognitive assistance and telemonitoring for&nbsp;ADL, as well as tools to gather ecological medical&nbsp;data through two connected sub-applications implemented in PDA: one for the patients, the other for&nbsp;the caregivers. On the one hand, the patients can consult their personalized list of ADL, and validate those&nbsp;which they actually realize. On another hand, they&nbsp;have the possibility to notify the caregivers when they&nbsp;feel a symptom, and to precise at which intensity.&nbsp;The caregivers can verify whether the patients validated their ADL, and they can consult information&nbsp;about intensity, frequency and time of apparition of&nbsp;the symptoms signaled by their patients. It is important</span></p><div>
<p><span class="font13">Downloaded by [McMaster University] at 11:49 28 December 2014</span></p></div><br clear="all">
<p><span class="font13">to note that the lists of ADL and symptoms are personalized according to the wish of each patient. A more detailed description of Mobus is available below (in the&nbsp;“material” paragraph) and in Giroux et al. (2008).</span></p>
<p><span class="font13">To sum up,</span></p>
<ul style="list-style:none;"><li>
<p><a name="bookmark1"></a><span class="font13">• Schizophrenia leads to memory and executive&nbsp;impairments that reduce autonomy</span></p></li><li>
<p><a name="bookmark2"></a><span class="font13">• The efficacy of some ATC has been proven for&nbsp;people with memory and executive deficiencies due&nbsp;to neurodevelopmental and neurodegenerative illnesses, brain lesions (Wilson et al., 2001; Wilson&nbsp;et al., 1997) and mental retardation (Davies, Stock, &amp;&nbsp;Wehmeyer, 2002; LoPresti et al., 2004). Nevertheless,&nbsp;few ATC have been developed for psychiatric disorders, and none exist for schizophrenia people.&nbsp;Moreover, individuals with schizophrenia present&nbsp;specific patterns of cognitive troubles and need specific tools.</span></p></li><li>
<p><a name="bookmark3"></a><span class="font13">• Schizophrenia people are able to use PDAs, as the&nbsp;EMAc study revealed. However, EMAc is an efficient&nbsp;assessment tool rather than an assistive device.</span></p></li><li>
<p><a name="bookmark4"></a><span class="font13">• Mobus seems to be a complete and hopeful tool&nbsp;which could improve the autonomy of schizophrenia people by assisting them in the planning of their&nbsp;ADL, as well as providing ecological medical data.</span></p></li></ul>
<p><span class="font13">A conviviality study was conducted with the first version of Mobus. A conviviality study must satisfy technological and usability criteria. The usability&nbsp;criteria regroup efficacy, efficiency, and satisfaction&nbsp;criteria. It is also conducted to answer to the following&nbsp;questions:</span></p>
<ul style="list-style:none;"><li>
<p><a name="bookmark5"></a><span class="font13">• What are the technological limits of the device that&nbsp;could be enhanced ?</span></p></li><li>
<p><a name="bookmark6"></a><span class="font13">• Is the device easily accessible enough for the targeted&nbsp;user, as well as not too simple in order to stir up&nbsp;motivation?</span></p></li><li>
<p><a name="bookmark7"></a><span class="font13">• Does the device meet the needs of the users?</span></p></li><li>
<p><a name="bookmark8"></a><span class="font13">• Does the user appreciate the device?</span></p></li></ul>
<p><span class="font13">Our conviviality study revealed that schizophrenic people were able to use Mobus. Furthermore, the application was appreciated by both patients and caregivers&nbsp;(Sablier et al., 2007). This first study allowed us to&nbsp;improve the application, which was tested through the&nbsp;present pilot experiment.</span></p>
<h1><a name="bookmark9"></a><span class="font7" style="font-weight:bold;">HYPOTHESES</span></h1>
<p><span class="font13">More than 50% of ADL validation would reflect that patients used Mobus regularly, as well as signaling their&nbsp;symptoms at least one time per week. As no previous studies exist to provide reference rates, we chose&nbsp;values that were clinically consistent. Furthermore,&nbsp;we investigated the subjective appreciation of the&nbsp;device by the patients through a questionnaire for&nbsp;which the maximum score was five (see “Variables and&nbsp;Analysis” section below for a description of this appreciation questionnaire). We expected that the majority&nbsp;of the participants would attribute a score higher than&nbsp;2.5, which corresponds to an appreciation between&nbsp;“appreciated a bit” and “neutral position.” Finally, we&nbsp;expected that the use of Mobus would enhance the&nbsp;skills on neuropsychological tests.</span></p>
<h1><a name="bookmark10"></a><span class="font7" style="font-weight:bold;">OBJECTIVE</span></h1>
<p><span class="font13">Our aim was to explore the manner of usage and the appreciation, by schizophrenia people, of Mobus.&nbsp;The goal of using Mobus is to improve cognitive&nbsp;function as well as to treat impairments. As a matter&nbsp;of fact, we suppose that this external aid can compensate for cognitive handicap, as well as rehabilitate&nbsp;it. It means that the ATC first replace the cognitive function. Then, after a period of use, skills are&nbsp;developed and trained. Finally, the ATC can have longterm impact and induce stable improvements (Wilson&nbsp;et al., 2001). We also explored if the use of Mobus&nbsp;improved memory and executive functioning as well&nbsp;as autonomy of people with schizophrenia.</span></p>
<h1><a name="bookmark11"></a><span class="font7" style="font-weight:bold;">METHODOLOGY</span></h1>
<h1><a name="bookmark12"></a><span class="font7" style="font-weight:bold;">Ethic</span></h1>
<p><span class="font13">This research received ethic approval from the French General Management of Health (protocol&nbsp;06 053).</span></p>
<h1><a name="bookmark13"></a><span class="font7" style="font-weight:bold;">Participants</span></h1>
<p><span class="font13">Inclusion criteria were: diagnosis of schizophrenia according to DSM-IV criteria, age above 18, and&nbsp;treatment stable since at least 2 weeks. Fourteen&nbsp;individuals signed the consent form. Nine patients&nbsp;participated until the end of the experiment. See</span></p><div>
<p><span class="font4" style="font-weight:bold;">TABLE 1 </span><span class="font3" style="font-weight:bold;">Characteristics, participation duration and locations of patients involved </span><span class="font3" style="font-weight:bold;font-style:italic;">(N </span><span class="font3" style="font-style:italic;">=</span><span class="font3" style="font-weight:bold;"> 9)</span></p></div><br clear="all"><div>
<p><span class="font4">Medication Name</span></p></div><br clear="all"><div>
<p><span class="font13">Downloaded by [McMaster University] at 11:49 28 December 2014</span></p></div><br clear="all"><div>
<table border="1">
<tr><td></td><td style="vertical-align:middle;">
<p><span class="font4">Sex</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">Age</span></p></td><td>
<p><span class="font4">Subtype of schizophrenia</span></p></td><td>
<p><span class="font4">Disease duration</span></p></td><td>
<p><span class="font4" style="font-style:italic;">/</span><span class="font4"> dose (mg) </span><span class="font4" style="font-style:italic;">/ </span><span class="font4">dosage regimen</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">Locations</span></p></td><td>
<p><span class="font4">Participation duration</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font4">P1</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">F</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">30</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">Undifferentiated</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">13</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">Clozapine 300 mg</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">Supervised residence</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">5 months and</span></p></td></tr>
<tr><td></td><td></td><td></td><td></td><td></td><td style="vertical-align:bottom;">
<p><span class="font4">BID</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">+ </span><span class="font4">CPTTA<sup>a</sup></span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">10 days</span></p></td></tr>
<tr><td>
<p><span class="font4">P2</span></p></td><td>
<p><span class="font4">F</span></p></td><td>
<p><span class="font4">39</span></p></td><td>
<p><span class="font4">Paranoid</span></p></td><td>
<p><span class="font4">15</span></p></td><td>
<p><span class="font4">Aripiprazole 15 mg</span></p></td><td>
<p><span class="font4">Parents' home </span><span class="font6">+ </span><span class="font4">DH<sup>b</sup></span></p></td><td>
<p><span class="font4">5 months and</span></p></td></tr>
<tr><td></td><td></td><td></td><td></td><td></td><td>
<p><span class="font4">BID</span></p></td><td></td><td>
<p><span class="font4">15 days</span></p></td></tr>
<tr><td>
<p><span class="font4">P3</span></p></td><td>
<p><span class="font4">F</span></p></td><td>
<p><span class="font4">44</span></p></td><td>
<p><span class="font4">Residual</span></p></td><td>
<p><span class="font4">14</span></p></td><td>
<p><span class="font4">Risperidone Consta</span></p></td><td>
<p><span class="font4">Parents' home </span><span class="font6">+</span></p></td><td>
<p><span class="font4">6 months</span></p></td></tr>
<tr><td></td><td></td><td></td><td></td><td></td><td style="vertical-align:bottom;">
<p><span class="font4">LP 100 mg</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">CPTTA<sup>a</sup></span></p></td><td></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font4">P4</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">M</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">32</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">Paranoid</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">9</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">Olanzapine 15 mg</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">Mother's home </span><span class="font6">+</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">6 months</span></p></td></tr>
<tr><td></td><td></td><td></td><td></td><td></td><td></td><td>
<p><span class="font4">DH<sup>b</sup></span></p></td><td></td></tr>
<tr><td>
<p><span class="font4">P5</span></p></td><td>
<p><span class="font4">F</span></p></td><td>
<p><span class="font4">44</span></p></td><td>
<p><span class="font4">Undifferentiated</span></p></td><td>
<p><span class="font4">?</span></p></td><td>
<p><span class="font4">Olanzapine 5 mg</span></p></td><td>
<p><span class="font4">Parents' home </span><span class="font6">+</span></p></td><td>
<p><span class="font4">2 months and</span></p></td></tr>
<tr><td></td><td></td><td></td><td></td><td></td><td style="vertical-align:bottom;">
<p><span class="font4">Fluoxetine 20 mg</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">CPTTA<sup>a</sup></span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">20 days</span></p></td></tr>
<tr><td>
<p><span class="font4">P6</span></p></td><td>
<p><span class="font4">M</span></p></td><td>
<p><span class="font4">33</span></p></td><td>
<p><span class="font4">Undifferentiated</span></p></td><td>
<p><span class="font4">1</span></p></td><td>
<p><span class="font4">Amisulpride 400 mg</span></p></td><td>
<p><span class="font4">Parents' home</span></p></td><td>
<p><span class="font4">6 months</span></p></td></tr>
<tr><td>
<p><span class="font4">P7</span></p></td><td>
<p><span class="font4">M</span></p></td><td>
<p><span class="font4">25</span></p></td><td>
<p><span class="font4">Paranoid</span></p></td><td>
<p><span class="font4">1</span></p></td><td>
<p><span class="font4">Aripirazole 20 mg</span></p></td><td>
<p><span class="font4">Own home</span></p></td><td>
<p><span class="font4">2 months and</span></p></td></tr>
<tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="vertical-align:bottom;">
<p><span class="font4" style="font-style:italic;">7</span><span class="font4"> days</span></p></td></tr>
<tr><td>
<p><span class="font4">P8</span></p></td><td>
<p><span class="font4">F</span></p></td><td>
<p><span class="font4">33</span></p></td><td>
<p><span class="font4">Schizo-affective</span></p></td><td>
<p><span class="font4">7</span></p></td><td>
<p><span class="font4">Risperidone Consta</span></p></td><td>
<p><span class="font4">Supervised residence</span></p></td><td>
<p><span class="font4">2 months and</span></p></td></tr>
<tr><td></td><td></td><td></td><td>
<p><span class="font4">disorder</span></p></td><td></td><td>
<p><span class="font4">LP 50 mg</span></p></td><td></td><td>
<p><span class="font4">20 days</span></p></td></tr>
<tr><td>
<p><span class="font4">P9</span></p></td><td>
<p><span class="font4">F</span></p></td><td>
<p><span class="font4">52</span></p></td><td>
<p><span class="font4">Paranoid</span></p></td><td>
<p><span class="font4">7</span></p></td><td>
<p><span class="font4">Risperidone 2 mg BID</span></p></td><td>
<p><span class="font4">Hospital</span></p></td><td>
<p><span class="font4">2 months and</span></p></td></tr>
<tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>
<p><span class="font4">8 days</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1">a</span></p></td><td style="vertical-align:bottom;">
<p><span class="font9">CPTTA </span><span class="font2">=</span></p></td><td colspan="2" style="vertical-align:bottom;">
<p><span class="font9">Center for Part-Time and Therapeutic</span></p></td><td style="vertical-align:bottom;">
<p><span class="font9">Activities, <sup>b</sup>DH </span><span class="font2">=</span></p></td><td style="vertical-align:bottom;">
<p><span class="font9">Day Hospital.</span></p></td><td></td><td></td></tr>
</table>
<p><span class="font4" style="font-weight:bold;">TABLE 2 </span><span class="font3" style="font-weight:bold;">Characteristics, participation duration and locations of four patients who were excluded (</span><span class="font3" style="font-weight:bold;font-style:italic;">N</span><span class="font3"> = </span><span class="font3" style="font-weight:bold;">4) and one who abandoned</span></p></div><br clear="all"><div>
<table border="1">
<tr><td style="vertical-align:bottom;">
<p><span class="font4">Sex</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">Age</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">Subtype of schizophrenia</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">Disease duration</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">Medication</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">Steps completed</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">Locations</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">Exclusion (X) Abandon (A)</span></p></td><td>
<p><span class="font4">Reasons of exclusion or&nbsp;abandon</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font4">M</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">36</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">Undifferentiated</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">13</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">Aripiprazole</span></p>
<p><span class="font4">15 mg</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">T1, BL</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">Own home </span><span class="font6">+ </span><span class="font4">CPTTA<sup>a</sup></span></p></td><td style="vertical-align:middle;">
<p><span class="font4">X</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">Feeling of persecution</span></p></td></tr>
<tr><td>
<p><span class="font4">M</span></p></td><td>
<p><span class="font4">30</span></p></td><td>
<p><span class="font4">Disorganized</span></p></td><td>
<p><span class="font4">10</span></p></td><td>
<p><span class="font4">Aripiprazole</span></p>
<p><span class="font4">15 mg</span></p></td><td>
<p><span class="font4">T1, BL, T2, SP</span></p></td><td>
<p><span class="font4">Mother's home </span><span class="font6">+&nbsp;</span><span class="font4">DH<sup>b</sup></span></p></td><td>
<p><span class="font4">X</span></p></td><td>
<p><span class="font4">Delirium further to admission to a&nbsp;residence</span></p></td></tr>
<tr><td>
<p><span class="font4">M</span></p></td><td>
<p><span class="font4">28</span></p></td><td>
<p><span class="font4">Paranoid</span></p></td><td>
<p><span class="font4">3</span></p></td><td>
<p><span class="font4">Risperidone</span></p>
<p><span class="font4">8 mg</span></p></td><td>
<p><span class="font4">T1</span></p></td><td>
<p><span class="font4">Mother's home</span></p></td><td>
<p><span class="font4">X</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">Did not want to complete his BL-questionnaire,&nbsp;mother hostile&nbsp;to the&nbsp;experiment</span></p></td></tr>
<tr><td>
<p><span class="font4">M</span></p></td><td>
<p><span class="font4">22</span></p></td><td>
<p><span class="font4">Paranoid</span></p></td><td>
<p><span class="font4">8</span></p></td><td>
<p><span class="font4">Haloperidol</span></p>
<p><span class="font4">20 mg</span></p></td><td>
<p><span class="font4">T1, BL, T2, SP</span></p></td><td>
<p><span class="font4">Supervised residence</span></p></td><td>
<p><span class="font4">X</span></p></td><td>
<p><span class="font4">Relapse</span></p></td></tr>
<tr><td>
<p><span class="font4">F</span></p></td><td>
<p><span class="font4">35</span></p></td><td>
<p><span class="font4">Disorganized</span></p></td><td>
<p><span class="font4">1</span></p></td><td>
<p><span class="font4">Aripiprazole</span></p>
<p><span class="font4">15 mg</span></p></td><td>
<p><span class="font4">T1, BL, T2</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">Mother's home </span><span class="font6">+&nbsp;</span><span class="font4">CPTTA<sup>a</sup></span></p></td><td>
<p><span class="font4">A</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">Fear of technology,&nbsp;mother hostile</span></p></td></tr>
</table>
<p><span class="font4">to the experiment</span></p></div><br clear="all"><div>
<p><span class="font9"><sup>a</sup>CPTTA </span><span class="font2">= </span><span class="font9">Center for Part-Time and Therapeutic Activities; <sup>b</sup>DH </span><span class="font2">= </span><span class="font9">Day Hospital.</span></p></div><br clear="all"><div>
<p><span class="font13">Table 1 for characteristics of each participant. Reasons of exclusion from the study are presented in Table 2.&nbsp;Furthermore, this study involved nurses and a neuropsychologist from the Vinatier psychiatric hospital,&nbsp;France. The experimentation took place in the Center&nbsp;for Part Time and Therapeutic Activities (CPTTA),</span></p></div><br clear="all"><div>
<p><span class="font13">and in a Day Hospital (DH). Patients from DH and CPTTA are supposed to be able to live on their own.&nbsp;The living and health-care locations of each patient&nbsp;encountered are described in Tables 1 and 2. To sum&nbsp;up, this study involved patients from various locations,&nbsp;with various degrees of autonomy. Fortunately, the</span></p></div><br clear="all"><div>
<p><span class="font13">Downloaded by [McMaster University] at 11:49 28 December 2014</span></p></div><br clear="all">
<p><span class="font13">material presented here is highly customizable and can be adjusted to suit each individual.</span></p>
<h1><a name="bookmark14"></a><span class="font7" style="font-weight:bold;">Material</span></h1>
<p><span class="font13">Mobus provides two connected sub-applications implemented in PDA: one for the patients, the other&nbsp;for the caregivers (Figure 1).</span></p>
<h1><a name="bookmark15"></a><span class="font7" style="font-weight:bold;">Patient Application</span></h1>
<p><span class="font13">Patients can either consult their list of ADL or notify the caregivers about a symptom, simply by&nbsp;clicking on the words “act.” or “sympt.” displayed on&nbsp;the touch-screen (Figure 1a). During an interview, the&nbsp;patient is said to express which ADL and symptoms he&nbsp;would like to record. These lists are therefore totally&nbsp;individualized. A color code notifies when the activity has to be performed (Figure 2a). As soon as the&nbsp;patient has accomplished the current activity, he must&nbsp;click on the corresponding line. The click time is also&nbsp;recorded on a server and the ADL validation appears&nbsp;on the caregiver’s PDA. The user has also the possibility to record what symptom is being experienced&nbsp;and how intense it is (Figures 2c, 2d, 2e). This is&nbsp;recorded, and can be consulted by the caregiver on the&nbsp;server.</span></p>
<h1><a name="bookmark16"></a><span class="font7" style="font-weight:bold;">Caregiver Application</span></h1>
<p><span class="font13">The caregivers can create, modify, and delete the occurrence, date, and time of ADL, as well as the list of&nbsp;symptoms of each patient. The patients first plan their&nbsp;activities on a paper, and discuss with the caregiver&nbsp;about the symptoms that disturb them the most.&nbsp;Then, the caregivers record these data from their PDA.&nbsp;The steps needed for programming the schedule and&nbsp;symptoms on PDAs are therefore not realized by the&nbsp;patients, as it would have represented a complex and&nbsp;useless cognitive demand. When the patients have difficulties to determine which ADL should be recorded&nbsp;in their PDA, the caregivers are here to help them. It is&nbsp;then possible to remotely verify whether the ADL have&nbsp;been validated or not (Figure 2b). A complete technical&nbsp;description of the functioning of Mobus is available in&nbsp;Giroux et al. (2008).</span></p>
<p><span class="font13">In total, Mobus is not only a pager which provides a recall of activity that has to be done. First, Mobus&nbsp;provides a list of ADL organized in time. Then, a color&nbsp;code informs the user if its time to do the task (yellow),&nbsp;if its too late (red), or if the activity has to be done in&nbsp;the future (grey). Finally, patients must make an effort&nbsp;for organizing their activities which are then registered&nbsp;in the device by caregivers. These features are aimed at&nbsp;developing mainly planning skills.</span></p>
<h1><a name="bookmark17"></a><span class="font7" style="font-weight:bold;">Variables and Analysis</span></h1>
<p><span class="font13">“ADL recall” is the name of the function displayed by the software, whereas “ADL validation” is the&nbsp;variable measured to quantify how much patients used&nbsp;the “ADL recall” function. In the same way, “symptom notification” is the appellation of the function</span></p><div><img src="Sablier et al. - 2012 - Ecolog_files/Sablier et al. - 2012 - Ecolog-2.jpg" alt="" style="width:303pt;height:186pt;">
<p><span class="font4" style="font-weight:bold;">FIGURE 1 </span><span class="font3" style="font-weight:bold;">Main screens of Mobus: (a) The patient-application displays the present time, the next activity, and allows the patient to consult his</span><span class="font0" style="font-weight:bold;font-style:italic;">/</span><span class="font3" style="font-weight:bold;">her own list of activities (“act.”) and symptoms (“sympt.”); (b) The caregiver-application allows to consult patients’&nbsp;characteristics, their activities and symptoms, as well as other caregivers involved.</span></p></div><br clear="all"><div>
<p><span class="font13">Downloaded by [McMaster University] at 11:49 28 December 2014</span></p></div><br clear="all"><div><img src="Sablier et al. - 2012 - Ecolog_files/Sablier et al. - 2012 - Ecolog-3.jpg" alt="" style="width:420pt;height:280pt;">
<p><span class="font4" style="font-weight:bold;">FIGURE 2 </span><span class="font3" style="font-weight:bold;">(a) Patient’s PDA: a past activity is displayed in red (dark line “Swimming pool” on the figure), a present activity is displayed in yellow (ex: “Cooking” white line on the figure), and a future activity appears in grey (ex: “Medication”, bright grey line here). (b) The&nbsp;caregiver can remotely verify whether the patients validated their activities (green discs—bright discs here) or not (red—dark discs here).&nbsp;(c) Patients can signal anything they are experiencing, and precise at which intensity, from anywhere, at any time. For example, a patient&nbsp;signals here that he is feeling distressed. (d) A new window opens with some proposition of intensities. Here, the patient feels a weak&nbsp;distress. (e) A last window opens so that the patient can verify and confirm what he selected.</span></p></div><br clear="all">
<p><span class="font13">provided by Mobus, whereas “signaling symptoms” is the corresponding outcome.</span></p>
<h1><a name="bookmark18"></a><span class="font7" style="font-weight:bold;">ADL Validation</span></h1>
<p><span class="font13">The rate of use of the ADL recall function was calculated by multiplying the number of ADL actually validated by the patient by 100, and dividing the result&nbsp;by the total number of activities initially planned.&nbsp;A rate of 100% corresponds to a perfect use, whereas&nbsp;a rate of 0% means that the patient never used Mobus&nbsp;to validate his activities.</span></p>
<h1><a name="bookmark19"></a><span class="font7" style="font-weight:bold;">Reporting Symptoms</span></h1>
<p><span class="font13">The mean of use of the symptom notification per week was obtained by reporting the total number of&nbsp;symptoms signaled on the total number of days of&nbsp;use, then multiplied by 7. We also calculated the mean&nbsp;percentage of usage of this function among the whole&nbsp;duration of use of the device, in order to compare&nbsp;it to the rate of use of ADL recall. A rate of 100%&nbsp;corresponds to a mean of one use per day, so the rate&nbsp;could be above 100% if patients signaled more than&nbsp;an average of one symptom per day.</span></p>
<h1><a name="bookmark20"></a><span class="font7" style="font-weight:bold;">Appreciation Questionnaire</span></h1>
<p><span class="font13">The appreciation of Mobus was obtained with a questionnaire filled by the participant at the end of&nbsp;the experiment. The user was asked to answer on a&nbsp;6-point Likert scale (from 0 </span><span class="font4">= </span><span class="font13">“not at all” to 5 </span><span class="font4">= </span><span class="font13">“very&nbsp;much”) to 8 questions such as: “How much did you&nbsp;appreciate Mobus?” or “According to you, to what&nbsp;extent did Mobus improve your autonomy?” As each&nbsp;patient could answer to a different amount of questions whether he lived in a supervised residence or&nbsp;according to the functionalities he preferentially used,&nbsp;we calculated the mean score of appreciation for each&nbsp;patient. The best appreciation would also be represented by a score of five. We hoped that the majority&nbsp;of the patients would appreciate the device and give a&nbsp;score above 2.5 (the middle value). The repartition of&nbsp;the scores through our sample was observed with the&nbsp;calculation of the mean and the three quartiles </span><span class="font13" style="font-style:italic;">(Q</span><span class="font12">1</span><span class="font13">,&nbsp;</span><span class="font13" style="font-style:italic;">Q</span><span class="font12">2</span><span class="font13">, </span><span class="font13" style="font-style:italic;">Q</span><span class="font12"> 3</span><span class="font13">).</span></p><div>
<p><span class="font13">Downloaded by [McMaster University] at 11:49 28 December 2014</span></p></div><br clear="all">
<h1><a name="bookmark21"></a><span class="font7" style="font-weight:bold;">Social and Neuropsychological Assessments</span></h1>
<p><span class="font13">The French translation of the Independent Living Skills Scale (ILSS) (Cyr, Toupin, Lesage, &amp; Valiquette,&nbsp;1994) was used to assess the patients’ autonomy.&nbsp;Attention, planning skills and episodic memory&nbsp;were assessed with subtests of the CAmbridge&nbsp;Neuropsychological Test Automated Battery&nbsp;(CANTAB). The Paired Associate Learning (PAL)&nbsp;was used to assess episodic memory and learning&nbsp;skills (Levaux et al., 2007; Strip, Lecardeur &amp; Ali-Sephery, 2008), whereas the Stocking of Cambridge&nbsp;(SOC) was administered to evaluate planning and&nbsp;strategy (Green et al., 2009). The SOC measures&nbsp;the time taken by the participants to plan their&nbsp;movements, as well as the number of movements&nbsp;realized to accomplish the task. These variables are&nbsp;measured according to the number of maximum&nbsp;movements needed to reach the goal of the task.&nbsp;The PAL consists of one or more presentations&nbsp;of a set of stimuli and corresponding attempts to&nbsp;correctly recall the location of each. The software&nbsp;detects whether the location that the subject chose&nbsp;was correct, and elicits a score of errors according&nbsp;to the number of shapes. Finally, the participants’&nbsp;symptomatology, their quality of life and self-esteem&nbsp;were assessed.</span></p>
<p><span class="font13">Such an extensive measurement battery was chosen for this small sample study in order to obtain indicators&nbsp;of tendency for a next study with more patients and a&nbsp;control group.</span></p>
<h1><a name="bookmark22"></a><span class="font7" style="font-weight:bold;">Statistics</span></h1>
<p><span class="font13">Paired sample </span><span class="font13" style="font-style:italic;">t</span><span class="font13">-tests were conducted in order to compare mean scores before and after the use of&nbsp;Mobus. Fisher’s correlations were calculated in order&nbsp;to investigate the link between the use of Mobus and&nbsp;scores on scales.</span></p>
<h1><a name="bookmark23"></a><span class="font7" style="font-weight:bold;">Procedure</span></h1>
<p><span class="font13">Interviews were organized between the experimenter, the patient, and a caregiver before and after the use of Mobus. Participants were informed about&nbsp;the progress and goals of the experiment and signed&nbsp;consent forms. Mobus was presented to the patient&nbsp;and each function was explained and tested until&nbsp;the patient managed to use it without any help.&nbsp;Patients used their PDAs, specially customized according to their needs, during six weeks. Social and&nbsp;neuropsychological assessments (ILSS and CANTAB)&nbsp;were collected before and after the use of Mobus, for&nbsp;example, during each interview.</span></p>
<h1><a name="bookmark24"></a><span class="font7" style="font-weight:bold;">RESULTS</span></h1>
<p><span class="font13">The rates of use of both functionalities provided by Mobus (ADL recall and symptom notification), as well&nbsp;as the mean scores of appreciation by the each patient,&nbsp;are presented in Figure 3.</span></p>
<h1><a name="bookmark25"></a><span class="font7" style="font-weight:bold;">ADL Validation</span></h1>
<p><span class="font13">Patients validated a mean of 42.61% of activities. The majority (38%) were validated during the planned&nbsp;periods, whereas 31% and 27% were validated too soon&nbsp;or too late, respectively. A third of the patients used&nbsp;Mobus for validating more than 82% of their activities&nbsp;(P2, P4, and P6).</span></p>
<h1><a name="bookmark26"></a><span class="font7" style="font-weight:bold;">Symptom Notification</span></h1>
<p><span class="font13">Patients signaled a mean of 1.01 symptoms per week. In total, they used this function with a mean&nbsp;of 14.44% of the total use-time. Two patients used it&nbsp;more than average (P1 and P9). Four patients notified&nbsp;only one symptom, on one occasion. Only one patient&nbsp;never used the function (P4). Sixty-two percent of the&nbsp;symptoms were signaled after noon.</span></p>
<h1><a name="bookmark27"></a><span class="font7" style="font-weight:bold;">Comparison of Both Functions</span></h1>
<p><span class="font13">As it can be seen on Figure 3, the highest users of “ADL recall” (P2, P4, and P6) were not the same&nbsp;people as the highest users of “symptom notification”&nbsp;(P1 and P9). Furthermore, as observed in Figure 3,&nbsp;the majority of participants (P1, P6, P5, P2, P7, and&nbsp;P4) used more the “ADL recall” than the “symptom&nbsp;notification” function.</span></p>
<h1><a name="bookmark28"></a><span class="font7" style="font-weight:bold;">Appreciation</span></h1>
<p><span class="font13">In Figure 3, data are ranged by increasing score of appreciation: from the participant who appreciated&nbsp;Mobus the less (P8 gave a mean score of 0.4) to the&nbsp;person who appreciated Mobus the best (P4 gave the</span></p><div><img src="Sablier et al. - 2012 - Ecolog_files/Sablier et al. - 2012 - Ecolog-4.jpg" alt="" style="width:354pt;height:234pt;">
<p><span class="font4" style="font-weight:bold;">FIGURE 3 </span><span class="font3" style="font-weight:bold;">Bars represent the rates of use of the “ADL recall” and “symptom notification” functions by the patients. The dotted line represents the middle value of the appreciation score. The white line represents the scores of appreciation of the device by the users.&nbsp;Data ranged by increasing score of appreciation: from the participant who appreciated Mobus the less (P8 gave a score of 0.4) to the&nbsp;person who appreciated Mobus the best (P4 gave the maximum score). For example, P4 validated all his ADL and appreciated Mobus a&nbsp;lot, whereas he signalled zero symptom; P6 appreciated not much the device (1.3</span><span class="font0" style="font-weight:bold;font-style:italic;">/</span><span class="font3" style="font-weight:bold;">5) and signalled a few symptom (10.6%), whereas she&nbsp;validated 100% of her ADL; P3 declared that he appreciated Mobus a lot (4.2</span><span class="font0" style="font-weight:bold;font-style:italic;">/</span><span class="font3" style="font-weight:bold;">5), whereas he seems to have not use it a lot (he validated&nbsp;only 8.75% of their ADL and used the symptom function 12.5% of the time per week, that is, less than one time per week).</span></p></div><br clear="all"><div>
<p><span class="font13">Downloaded by [McMaster University] at 11:49 28 December 2014</span></p></div><br clear="all">
<p><span class="font13">maximum score). The dotted line in Figure 3 delimits the scores above and under the expected value (2.5).&nbsp;Among our sample, the repartition of the scores was&nbsp;(Mean, </span><span class="font13" style="font-style:italic;">Q</span><span class="font12" style="font-style:italic;">1</span><span class="font13" style="font-style:italic;">, Q</span><span class="font12" style="font-style:italic;">2</span><span class="font13">, </span><span class="font13" style="font-style:italic;">Q</span><span class="font12">3</span><span class="font13">) </span><span class="font4">= </span><span class="font13">(2.27, 1.0, 1.7, 3.8). No significant correlation was found between the scores of&nbsp;appreciation and, neither the rates of ADL validations,&nbsp;nor the mean notification of symptoms per week.</span></p>
<h1><a name="bookmark29"></a><span class="font7" style="font-weight:bold;">Social and Neuropsychological Assessments</span></h1>
<p><span class="font13">The results of ILSS and subtests of CANTAB scores, as well as other neuropsychological assessments, are&nbsp;presented in Table 3.</span></p>
<p><span class="font13">Significant enhancement between Baseline and Endpoint was found for the “Food” subscale of the&nbsp;ILSS </span><span class="font13" style="font-style:italic;">(t(8) =</span><span class="font13"> 2.32, </span><span class="font13" style="font-style:italic;">p =</span><span class="font13"> .049). The “Food” subscale&nbsp;in ILSS measures the ability of cooking meals, managing grocery, eating, and conserving healthy food.&nbsp;An increase in this score means that the individual&nbsp;becomes more autonomous related to meals and food.</span></p>
<p><span class="font13">Furthermore, a significant decrease in the mean subsequent thinking time for the SOC subtest of the CANTAB appeared (</span><span class="font13" style="font-style:italic;">t</span><span class="font13">(8) </span><span class="font4">= </span><span class="font13">3.67, </span><span class="font13" style="font-style:italic;">p =</span><span class="font13"> .006), which&nbsp;means that performance on this test was enhanced. The&nbsp;SOC subtest of the CANTAB assesses planning and&nbsp;strategy skills. There were no significant improvements&nbsp;on other measures.</span></p>
<h1><a name="bookmark30"></a><span class="font7" style="font-weight:bold;">DISCUSSION Promising Results</span></h1>
<p><span class="font13">This pilot study was aimed at verifying whether schizophrenia people would be able to use Mobus&nbsp;regularly, by validating more than 50% of their ADL&nbsp;and by signaling at least one symptom per week.&nbsp;Actually, the patients validated a mean of 1.01 symptoms per week, but validated a mean of 42.61% of&nbsp;their ADL. Nevertheless, a third of the patients used&nbsp;Mobus for validating more than 82% of their activities.&nbsp;Furthermore, when they did use Mobus, most of the&nbsp;participants validated their ADL during the planned&nbsp;periods. This is a promising indication of potential&nbsp;effective use of Mobus in the future. On another&nbsp;hand, the fact that symptoms seem to be experienced&nbsp;mainly after noon could be taken into account in&nbsp;the treatment by caregivers. Interestingly, the highest users of “ADL recall” (P2, P4, and P6) were not&nbsp;the same people as the highest users of “symptom</span></p><div>
<p><span class="font13">Downloaded by [McMaster University] at 11:49 28 December 2014</span></p></div><br clear="all"><div>
<p><span class="font4" style="font-weight:bold;">TABLE 3 </span><span class="font3" style="font-weight:bold;">Clinical, psychosocial functioning, and cognitive scores </span><span class="font3" style="font-weight:bold;font-style:italic;">(p</span><span class="font3" style="font-weight:bold;"> values are indicated for significant </span><span class="font3" style="font-weight:bold;font-style:italic;">f</span><span class="font3" style="font-weight:bold;">-tests)</span></p>
<table border="1">
<tr><td style="vertical-align:bottom;">
<p><span class="font4" style="font-style:italic;">N =</span><span class="font4"> 9</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">Baseline mean </span><span class="font4" style="font-style:italic;">(SD)</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">Endpoint mean (</span><span class="font4" style="font-style:italic;">SD</span><span class="font4">)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4" style="font-style:italic;">P</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font4">PANSS<sup>a</sup></span></p></td><td></td><td></td><td></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font4">Positive scale</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">14.11 (6.03)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">15.00 (5.61)</span></p></td><td></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font4">Negative scale</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">13.78 (3.15)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">14.22 (5.29)</span></p></td><td></td></tr>
<tr><td>
<p><span class="font4">General scale</span></p></td><td>
<p><span class="font4">32.56 (5.53)</span></p></td><td>
<p><span class="font4">32.56 (5.92)</span></p></td><td></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font4">ILSS<sup>b</sup></span></p></td><td></td><td></td><td></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font4">Total score</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">0.83 (0.18)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">0.85 (0.18)</span></p></td><td></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font4">Personal hygiene</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">0.83 (0.18)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">0.85 (0.18)</span></p></td><td></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font4">Appearance and clothes</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">0.78 (0.21)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">0.81 (0.21)</span></p></td><td></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font4">Cleaning</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">0.70 (0.29)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">0.81 (0.27)</span></p></td><td></td></tr>
<tr><td>
<p><span class="font4">Food</span><span class="font5">*</span></p></td><td>
<p><span class="font4">0.70 (0.21)</span></p></td><td>
<p><span class="font4">0.81 (0.28)</span></p></td><td>
<p><span class="font4">.049</span></p></td></tr>
<tr><td>
<p><span class="font4">Health</span></p></td><td>
<p><span class="font4">0.88 (0.20)</span></p></td><td>
<p><span class="font4">0.94 (0.17)</span></p></td><td></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font4">Money (</span><span class="font4" style="font-style:italic;">N</span><span class="font6"> = </span><span class="font4">8)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">0.62 (0.27)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">0.72 (0.29)</span></p></td><td></td></tr>
<tr><td>
<p><span class="font4">Leisure</span></p></td><td>
<p><span class="font4">0.65 (0.18)</span></p></td><td>
<p><span class="font4">0.67 (0.20)</span></p></td><td></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font4">Quality of life</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">15.31 (5.98)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">16.33 (5.45)</span></p></td><td></td></tr>
<tr><td>
<p><span class="font4">Self-esteem</span></p></td><td>
<p><span class="font4">32.67 (3.08)</span></p></td><td>
<p><span class="font4">30.89 (4.28)</span></p></td><td></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font4">CANTAB<sup>c</sup></span></p></td><td></td><td></td><td></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font4">MOT mean error</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">8.84 (3.54)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">8.20 (2.06)</span></p></td><td></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font4">MOT mean latency</span><span class="font5">*</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">840.99 (41.01)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">941.66 (159.03)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">.031</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font4">PAL total errors (adjusted)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">28.60 (7.46)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">24.33 (23.69)</span></p></td><td></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font4">PAL total errors (6 shapes, adjusted)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">6.80 (8.69)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">3.44 (4.69)</span></p></td><td></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font4">SOC mean initial thinking time (5 moves)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">9,824.90 (5383.27)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">5,283.47 (2882.67)</span></p></td><td></td></tr>
<tr><td>
<p><span class="font4">SOC mean subsequent thinking time (5 moves)</span><span class="font5">*</span></p></td><td>
<p><span class="font4">1,521.75 (2000.41)</span></p></td><td>
<p><span class="font4">604.47 (641.99)</span></p></td><td>
<p><span class="font4">.006</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font4">SOC problems solved in minimum moves</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">6.80 (2.39)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">6.78 (1.30)</span></p></td><td></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font4">SWM between errors</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">34.60 (20.51)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">31.44(16.71)</span></p></td><td></td></tr>
<tr><td>
<p><span class="font4">SWM strategy</span></p></td><td>
<p><span class="font4">33.80 (6.63)</span></p></td><td>
<p><span class="font4">33.33 (6.06)</span></p></td><td></td></tr>
</table>
<p><span class="font9"><sup>a</sup>Positive and Negative Syndrome Scale. <sup>b</sup>Independent Living Skills Scale.&nbsp;<sup>c</sup>CAmbridge Neuropsychological Test Automated Battery.&nbsp;</span><span class="font5">’</span><span class="font9">Results are significant.</span></p></div><br clear="all">
<p><span class="font13">notification” (P1 and P9). Patients may find it difficult to use both functions. However, this explanation does not correspond to the reports of the patients&nbsp;themselves, who found the application easy to use.&nbsp;Furthermore, the majority of participants used more&nbsp;the “ADL recall” than the “symptom notification”&nbsp;function. Participants could have been more motivated&nbsp;to improve their autonomy than to report their symptoms, which focus on negative aspects of the disease.&nbsp;Knowing that people with schizophrenia have difficulties recognizing their illness, we changed the name of&nbsp;this function in the next study, in order to motivate&nbsp;more patients to use it. The name “Experiences” would&nbsp;be better, as it would avoid focusing on symptoms,&nbsp;which is far less stigmatizing and closer to modern approaches to rehabilitation centered to recovery&nbsp;of people. On another hand, the participants experiencing more frequent symptom attacks may have&nbsp;decreased attention on the tasks they had to do. Finally,&nbsp;we expected that the use of Mobus would enhance the&nbsp;skills on neuropsychological tests.</span></p>
<p><span class="font13">The significant enhancement on the score at the “Food” subscale of the ILSS could mean that, at the end&nbsp;of the experiment, patients performed better at tasks&nbsp;related to food. On another hand, significant decrease&nbsp;was found on the mean subsequent thinking time of&nbsp;the SOC. This could reflect that our procedure might&nbsp;have led to an improvement in executive functioning,&nbsp;as we expected. Nevertheless, these results must be&nbsp;replicated with more subjects and a control group.</span></p>
<h1><a name="bookmark31"></a><span class="font7" style="font-weight:bold;">Complementary Hopeful Observations</span></h1>
<p><span class="font13">Some patients had few activities (social avoidance, apragmatism): planning ADL with an entertaining tool&nbsp;could have encouraged them to plan new occupations.</span></p><div>
<p><span class="font13">Downloaded by [McMaster University] at 11:49 28 December 2014</span></p></div><br clear="all">
<p><span class="font13">For example, P2 took steps to register for a bicycle course, P7 participated in a soccer course, and P3 spent more time in her own apartment (gradually&nbsp;leaving parents’ home). It is important to add here&nbsp;the importance of occupational rehabilitation work in&nbsp;parallel with Mobus. As a matter of fact, the caregivers supported the mobilization, the reintegration of&nbsp;significant activities and the development of an occupational schedule rewarding for the person. Overall,&nbsp;the PDA personalization was very important, because&nbsp;of the various degree of autonomy and occupation of&nbsp;patients. Finally, some of them reported that they used&nbsp;“ADL recall” at the beginning, but after several days,&nbsp;they began to habituate to the repeated activities and&nbsp;remembered them without reminders. This encouraging result represents the potential that some people will&nbsp;gain in their ability to learn and organize their activities&nbsp;through use of Mobus.</span></p>
<h1><a name="bookmark32"></a><span class="font7" style="font-weight:bold;">Limits</span></h1>
<p><span class="font13">Through Mobus, patients are supposed to be permanently connected to their caregivers. This is aimed at avoiding isolation, and providing a reassuring environment to the patient. Nevertheless, some schizophrenia people can experience paranoid symptoms (which&nbsp;belong to positive symptomatology). When patients&nbsp;strongly presented this symptom, we observed that it&nbsp;was difficult, indeed impossible, to ask them to use&nbsp;Mobus. As a matter of fact, these patients fear more&nbsp;than others from being observed. For them, Mobus can&nbsp;represent the threatening eye of “big brother,” instead&nbsp;of the friendly hand of the caregiver. On another hand,&nbsp;the fact that patients validate their ADL does not mean&nbsp;that they actually did them. Nevertheless, it would be&nbsp;unethical to watch them, as well as to force them to&nbsp;complete their activities.</span></p>
<p><span class="font13">Mainly, the PDAs experienced connection breakdown. Consequently, some tasks were not updated, and sometimes, participants could not validate an&nbsp;activity, because they did not see it on their diary.&nbsp;Thus, the device was not constantly functional, what&nbsp;could explain the weak rate of ADL validation. In fact,&nbsp;some participants may have used the “symptom&nbsp;notification,” which did not encounter any problems,&nbsp;rather than the “ADL recall” which did not update.&nbsp;On another hand, some patients used the “ADL recall”&nbsp;function despite the technical problems and were also&nbsp;less motivated to use the “symptom notification.”</span></p>
<p><span class="font13">Furthermore, these technical problems could explain the weak scores on the appreciation questionnaire. As a matter of fact, more than the half of&nbsp;our sample attributed a score under 1.7 to Mobus,&nbsp;and only 3 participants gave a score higher than 2.5,&nbsp;which was the expected value. Among these persons,&nbsp;P4 was a high user of “ADL recall” and P9 was a high&nbsp;user of “symptom notification.” Nevertheless, it is&nbsp;worth noticing that, for other patients, the subjective&nbsp;appreciation of the device seems to be in contradiction&nbsp;with its use. For example, P1, P2, and P6 had a weak&nbsp;appreciation of Mobus whereas they noticeably used&nbsp;it. This could explain the lack of correlation between&nbsp;these amounts of use and the appreciation of Mobus.&nbsp;Thus, if the connection problem was the core factor&nbsp;of weak appreciation, it did not prevent patients from&nbsp;using the device. We also can hopefully imagine that,&nbsp;with a good functioning of Mobus, most of patients&nbsp;would use it, but also appreciate it. As a matter of fact,&nbsp;the results of P4 show that it is possible, with 100% of&nbsp;validated ADL and a total appreciation of the device.</span></p>
<p><span class="font13">Furthermore, the connection breakdowns could have biased neuropsychological measures. This bias,&nbsp;added to the small sample size and large intersubject&nbsp;variability, imposes to consider statistical analyses with&nbsp;caution. These data represent also indicators of tendency, and should be investigated again with a new&nbsp;version of Mobus and a control group.</span></p>
<p><span class="font13">Finally, the choice of the assessments can be discussed. As a matter of fact, the ILSS is more focused on daily living skills than on occupational schedule.&nbsp;An occupational questionnaire, such as the University&nbsp;of California, San Diego (UCSD) Performance-Based&nbsp;Skills Assessment (Patterson et al., 2001), for example,&nbsp;could be envisaged for future studies. Furthermore, the&nbsp;appreciation questionnaire has not been validated, thus&nbsp;the results can be contested. In the future, Quebec User&nbsp;Evaluation of Satisfaction with assistive Technology&nbsp;(QUEST) (Demers, Weiss-Lambrou, &amp; Ska, 2002)&nbsp;could be used.</span></p>
<h1><a name="bookmark33"></a><span class="font7" style="font-weight:bold;">Solution</span></h1>
<p><span class="font13">To avoid the feeling of being watched, and to improve the feeling of managing one’s own schedule,&nbsp;a function could be added, which would allow the person to choose when he</span><span class="font13" style="font-style:italic;">/</span><span class="font13">she wants to be logged and&nbsp;which data he</span><span class="font13" style="font-style:italic;">/</span><span class="font13">she agrees to share. The use of such&nbsp;functionality would depend on the ability and the&nbsp;wish of choosing, which themselves depend on the&nbsp;symptoms intensity and on the cognitive skills of each&nbsp;patient. As a matter of fact, this would make the device&nbsp;more complex (good cognitive skills needed), and give&nbsp;new responsibility to the user, which is not necessarily&nbsp;a wish from each patient. Thus, this possibility, which&nbsp;would correspond to the model of recovery, should&nbsp;be another personalized functionality according to the&nbsp;patient’s profile, like “ADL recall” and “symptoms&nbsp;notification.”</span></p>
<p><span class="font13">Concerning technical problems, programmers detected that new connection problems arose from&nbsp;mismatches in the code. Thus, they reshaped the entire&nbsp;underlying program which is now much more stable&nbsp;and connection problems have been repaired.</span></p><div>
<p><span class="font13">Downloaded by [McMaster University] at 11:49 28 December 2014</span></p></div><br clear="all">
<h1><a name="bookmark34"></a><span class="font7" style="font-weight:bold;">Future Directions</span></h1>
<p><span class="font13">It is important to use Mobus in a real context of rehabilitation where the reintegration of significant activities and the development of an occupational&nbsp;schedule are part of the rehabilitation plan. We are&nbsp;currently testing the enhanced version of Mobus in a&nbsp;randomized controlled study involving two groups of&nbsp;people with schizophrenia. Furthermore, Mobus could&nbsp;be tested by people with cognitive impairments due&nbsp;to other neuropsychological disorder. As a matter of&nbsp;fact, it could help individuals with brain traumatic&nbsp;injuries, as well as neurodegenerative or neurodevel-opmental diseases. Finally, the effect of the age could&nbsp;be investigated, as younger patients could be thought&nbsp;to be more familiar with new technologies than older&nbsp;people.</span></p>
<h1><a name="bookmark35"></a><span class="font7" style="font-weight:bold;">CONCLUSION</span></h1>
<p><span class="font13">Mobus provided ecological data that could be valuable for clinical follow-up of schizophrenia people. This pilot study was useful to improve Mobus as well&nbsp;as to provide clues for developing new technologies for&nbsp;cognitive rehabilitation. Overall, this study highlights&nbsp;the importance of an integrated approach that links&nbsp;together complementary therapeutic modalities such&nbsp;as cognitive remediation (Demily &amp; Franck, 2008) and&nbsp;social rehabilitation. The use of Mobus will be optimal&nbsp;in this context of integrated approaches.</span></p>
<h1><a name="bookmark36"></a><span class="font7" style="font-weight:bold;">REFERENCES</span></h1>
<p><span class="font9">Bowie, C. R., &amp; Harvey, P. D. (2005). Cognition in schizophrenia: Impairments, determinants, and functional importance. </span><span class="font9" style="font-style:italic;">Psychiatric&nbsp;Clinics of North America, 28</span><span class="font9">(3), 613-633.</span></p>
<p><span class="font9">Chambon, V., Franck, N., Koechlin, E., Fakra, E., Ciuperca, G., Azorin, J. M., et al. (2008). The architecture of cognitive control in schizophrenia. </span><span class="font9" style="font-style:italic;">Brain, 131(4),</span><span class="font9"> 962-970.</span></p>
<p><span class="font9">Cole, E. (1999). Cognitive prosthetics: An overview to the method of treatment. </span><span class="font9" style="font-style:italic;">NeuroRehabilitation, 12,</span><span class="font9"> 39-51.</span></p>
<p><span class="font9">Cyr, M., Toupin, J., Lesage, A. D., &amp; Valiquette, C. A. (1994). Assessment of independent living skills for psychotic patients: Further validity and&nbsp;reliability. </span><span class="font9" style="font-style:italic;">Journal of Nervous and Mental Disease, 182</span><span class="font9">(2), 91-97.</span></p>
<p><span class="font9">Davies, D. K., Stock, S. E., &amp; Wehmeyer, M. L. (2002). Enhancing independent time-management skills of individuals with mental retardation using a Palmtop personal computer. </span><span class="font9" style="font-style:italic;">Mental Retard, 40(5),</span><span class="font9"> 358-365.</span></p>
<p><span class="font9">Demers, L., Weiss-Lambrou, R., &amp; Ska, B. (2002). The Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0):&nbsp;An overview and recent progress. </span><span class="font9" style="font-style:italic;">Technology and Disability</span><span class="font9">, </span><span class="font9" style="font-style:italic;">14</span><span class="font9">(3),&nbsp;101-105.</span></p>
<p><span class="font9">Demily, C., &amp; Franck, N. (2008). Cognitive remediation: a promising tool for the treatment of schizophrenia. </span><span class="font9" style="font-style:italic;">Expert Review of Neurotherapeutics</span><span class="font9">, </span><span class="font9" style="font-style:italic;">8</span><span class="font9">(7), 1029-1036.</span></p>
<p><span class="font9">Giroux, S., Pigot, H., Paccoud, B., Pache, D., Sablier, J., &amp; Stip, E. (2008). Enhancing a mobile cognitive orthotic: A user-centered design&nbsp;approach. </span><span class="font9" style="font-style:italic;">International Journal of ARM, 9</span><span class="font9">(1), 1-12.</span></p>
<p><span class="font9">Granholm, E., Loh, C., &amp; Swendsen, J. (2009). Feasability and validity of computerised ecological momentary assessment in schizophrenia.&nbsp;</span><span class="font9" style="font-style:italic;">Schizophrenia Bulletin</span><span class="font9">, </span><span class="font9" style="font-style:italic;">34</span><span class="font9">(3), 507-514.</span></p>
<p><span class="font9">Green, M. F. (1996). What are the functional consequences of neu-rocognitive deficits in schizophrenia? </span><span class="font9" style="font-style:italic;">American Journal of Psychiatry, 153</span><span class="font9">(3), 321-330.</span></p>
<p><span class="font9">Green, C. R., Mihic, A. M., Nikkel, S. M., Stade, S. C., Rasmussen, C., Munoz, D. P., &amp; Reynolds, J. N. (2009). Executive function&nbsp;deficits in children with fetal alcohol spectrum disorders (FASD) measured using the Cambridge Neuropsychological Tests Automated&nbsp;Battery (CANTAB). </span><span class="font9" style="font-style:italic;">Journal of Child Psychology and Psychiatry, 50(6),&nbsp;</span><span class="font9">688-697.</span></p>
<p><span class="font9">Levaux, M. N., Potvin, S., Sepehry, A. A., Sablier, J., Mendrek, A., &amp; Stip, E. (2007). Computerized assessment of cognition in schizophrenia: promises and pitfalls of CANTAB. </span><span class="font9" style="font-style:italic;">European Psychiatry</span><span class="font9">, </span><span class="font9" style="font-style:italic;">22</span><span class="font9">(2),&nbsp;104-115.</span></p>
<p><span class="font9">Levinson, R. (1997). PEAT: The planning and execution assistant and training system. </span><span class="font9" style="font-style:italic;">Journal of Head Trauma Rehabilitation, 12</span><span class="font9">(2), 769-775.</span></p>
<p><span class="font9">LoPresti, E., Mihailidis, A., &amp; Kirsch, N. (2004). Assistive technology for cognitive rehabilitation: State of the art. </span><span class="font9" style="font-style:italic;">Neuropsychological&nbsp;Rehabilitation, 14</span><span class="font9">(1</span><span class="font9" style="font-style:italic;">/</span><span class="font9">2), 5-39.</span></p>
<p><span class="font9">Norman, R. M., Malla, A. K., Cortese, L., Cheng, S., Diaz, K., McIntosh, E., et al. (1999). Symptoms and cognition as predictors of community&nbsp;functioning: A prospective analysis. </span><span class="font9" style="font-style:italic;">Am J Psychiatry, 156(3),</span><span class="font9"> 400-405.</span></p>
<p><span class="font9">Patterson, T L., Goldman, S., McKibbin, C. L., Hughs, T., &amp; Jeste, D.</span></p>
<p><span class="font9">V. (2001). UCSD performance-based skills assessment. </span><span class="font9" style="font-style:italic;">Schizophrenia Bulletin, 27(2),</span><span class="font9"> 235-245.</span></p>
<p><span class="font9">Sablier, J., Stip, E., &amp; Franck, N. (2009). Cognitive remediation and cognitive assistive technologies in schizophrenia. </span><span class="font9" style="font-style:italic;">L'Encephale, 35,&nbsp;</span><span class="font9">160-167.</span></p>
<p><span class="font9">Sablier, J., Stip, E., Franck, N., Giroux, S., Pigot, H., Moreau, J., etal. (2007). Study on the convivial use of an electronic agenda by individuals with schizophrenia. </span><span class="font9" style="font-style:italic;">Sante Mentale au Quebec, 32</span><span class="font9">(2), 209-224.</span></p>
<p><span class="font9">Stip, E., Lecardeur, L., &amp; Ali-Sepehry, A. (2008). Computerized assessment of neurocognition in schizophrenia: An exploratory meta-analysis of&nbsp;CANTAB findings. </span><span class="font9" style="font-style:italic;">European Psychiatric Review, 1</span><span class="font9">(2), 48-54.</span></p>
<p><span class="font9">Wilson, B. A., Emslie, H. C., Quirk, K., &amp; Evans, J. J. (2001). Reducing everyday memory and planning problems by means of a paging system: A randomised control crossover study. </span><span class="font9" style="font-style:italic;">Journal of Neurology,&nbsp;Neurosurgery and Psychiatry, 70</span><span class="font9">(4), 477-482.</span></p>
<p><span class="font9">Wilson, B. A., Evans, J. J., Emslie, H., &amp; Malinek, V. (1997). Evaluation of NeuroPage: A new memory aid. </span><span class="font9" style="font-style:italic;">Journal of Neurology, Neurosurgery,&nbsp;and Psychiatry, 63</span><span class="font9">(1), 113-115.</span></p>
<p><span class="font4">77</span></p>
<p><span class="font4" style="font-weight:bold;font-style:italic;">Mobus, An Assistive Technology for Schizophrenia</span></p>
</body>
</html>